For the quarter ending 2026-03-31, ALXO had $15,911K increase in cash & cash equivalents over the period. -$18,698K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Clinical And Development Costs | 8,280 | - | - | - |
| Preclinical Costs | -65 | - | - | - |
| Personnel And Related Costs | 3,175 | - | - | - |
| Stockbased Compensation Expense | 1,201 | - | - | - |
| Other Research Costs | 1,015 | - | - | - |
| Research and development expenses | 13,606 | 17,645 | 59,351 | - |
| General and administrative expenses | 5,360 | 5,376 | 18,474 | - |
| Impairment of long-lived assets | - | 0 | 3,175 | - |
| Total impairment charge | - | 0 | 3,175 | - |
| Loss from operations | -18,966 | -23,021 | -81,000 | - |
| Interest income | 1,182 | 573 | 3,391 | - |
| Interest expense | 331 | 383 | 1,219 | - |
| Other income (expense), net | 188 | -17 | -19 | - |
| Net loss | -17,927 | -22,848 | -78,847 | - |
| Stock-based compensation | 2,509 | 2,706 | 9,873 | - |
| Depreciation and amortization | 150 | 151 | 555 | - |
| Non-cash lease costs | 388 | 386 | 1,333 | - |
| Net accretion of discounts on investments | 199 | 186 | 1,056 | - |
| Accretion of term loan discount and issuance costs | 68 | 72 | 208 | - |
| Impairment charge | - | 0 | 3,175 | - |
| Prepaid expenses and other current assets | -697 | 47 | -705 | - |
| Other assets | -306 | -5,007 | 5,693 | - |
| Accounts payable | -1,210 | -1,669 | 2,090 | - |
| Payable and accrued liabilities due to related party | - | 0 | -149 | - |
| Accrued expenses and other current liabilities | -3,012 | -2,148 | 4,150 | - |
| Other non-current liabilities | -418 | -404 | -1,506 | - |
| Net cash used in operating activities | -18,648 | -18,980 | -65,162 | - |
| Purchase of investments | 124,486 | 5,974 | 45,619 | - |
| Maturities of investments | 19,500 | 17,256 | 117,135 | - |
| Purchase of property and equipment | 50 | 49 | 163 | - |
| Net cash (used in) provided by investing activities | -105,036 | 11,233 | 71,353 | - |
| Proceeds from equity offering | 150,000 | - | - | - |
| Payments of issuance costs related to equity offering | 9,477 | - | - | - |
| Proceeds from atm offering, net of commissions | 11 | 1,316 | 372 | - |
| Proceeds from exercise of stock options under equity incentive plan | 670 | 13 | 1 | - |
| Proceeds from issuance of common stock under employee stock purchase plan | - | 9 | 15 | - |
| Proceeds from exercise of pre-funded warrant | 3 | - | - | - |
| Principal payments on finance leases | 307 | 225 | 704 | - |
| Principal payments on term loan | 1,305 | 435 | - | - |
| Net cash provided by financing activities | 139,595 | 678 | -316 | - |
| Restricted cash (included in other assets) | - | - | - | 66 |
| Net decrease in cash, cash equivalents and restricted cash | 15,911 | -7,069 | 5,875 | - |
| Cash and cash equivalents | - | - | - | 19,302 |
| Cash, cash equivalents and restricted cash at beginning of year | 16,439 | 23,508 | 19,368 | - |
| Cash, cash equivalents and restricted cash at end of period | 32,350 | 16,439 | 23,508 | 19,368 |
ALX ONCOLOGY HOLDINGS INC (ALXO)
ALX ONCOLOGY HOLDINGS INC (ALXO)